COMPANY PROFILE

AbTis

Explore full profile

Cost-effective ADC production with high therapeutic index and rapid druggability verification

Gunpo-si, South KoreaFounded 2016Biotech & Life Sciences

Valuation $100–250M Last recorded · 2023

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About AbTis

AbTis operates in the biopharmaceutical sector, focusing on the development and production of Antibody-Drug Conjugates (ADCs). The company offers a proprietary linker platform that enhances the conjugation process, ensuring high yield and simplified purification. This approach not only reduces production costs but also increases the therapeutic index of ADCs. AbTis collaborates with both industrial and academic partners, providing them with the ability to verify the druggability of novel ADCs within a short timeframe of 2-3 weeks. The business model revolves around partnerships and collaborations, where AbTis leverages its technology to assist in ADC development, thereby generating revenue through service agreements and licensing. The company serves clients in the pharmaceutical and biotechnology industries, aiming to streamline ADC development and enhance therapeutic outcomes.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2016
Headquarters: Gunpo-si, South Korea
Employees: 20
Open positions: None listed
Dealroom signal: 24.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	Dec 2023	$0	—	Dong-A ST	↗
SERIES B✓Equity / VC	Mar 2023	$17M	$67M	Korea Venture Investment Corporation	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth
2026
2025
2024
2023
2022
2021		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

AbTis website traffic

Latest recorded traffic for AbTis is 1.8K monthly website visits, down 14.3% over the last three months.

Latest monthly visits1.8K 3-month web change-14.3%

Monthly website visitsApr 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BIBillionToOneThe only genetic testing platform that accurately and efficiently detects and measures disease at the molecular level	Menlo Park, United States	Operational	839	$391M	$4.3B
GTGemini TherapeuticsInnovative therapies targeting genetically defined subpopulations in dry AMD and related diseases	Cambridge, United States	Operational
DMDigma MedicalA clinical stage medical device company revolutionizing treatment of Type-2 Diabetes & NASH	Giv'at Shmuel, Israel	Operational
ANAnnoroadA leading developer and marketer on genomic innovation technologies for research and clinical market	Dongcheng District, China	Operational
STStorm TherapeuticsSmall molecule therapies targeting RNA modifying enzymes	Cambridge, United Kingdom	Operational
MOMorphogen-IXEngineered protein therapeutics for pulmonary arterial hypertension	Babraham, United Kingdom	Acquired
STSpur TherapeuticsGene therapies for Gaucher, Parkinson's, and cardiovascular diseases	Stevenage, United Kingdom	Acquired
ATAt-biotechHealth care company that creates technological automation and safety solutions for the healthcare sector	Madrid, Spain	Operational